Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study

IA. Van Assche, EA. Huis In 't Veld, K. Van Calsteren, M. van Gerwen, J. Blommaert, E. Cardonick, MJ. Halaska, R. Fruscio, M. Fumagalli, J. Lemiere, EM. van Dijk-Lokkart, C. Fontana, H. van Tinteren, J. De Ridder, M. van Grotel, MM. van den...

. 2023 ; 41 (8) : 1527-1532. [pub] 20230112

Language English Country United States

Document type Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23003840

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.This multicenter cohort study reports on the long-term effects of prenatal exposure to maternal cancer and its treatment on cognitive and behavioral outcomes in 9-year-old children. In total, 151 children (mean age, 9.3 years; range, 7.8-10.6 years) were assessed using a neurocognitive test battery and parent-report behavioral questionnaires. During pregnancy, 109 children (72.2%) were exposed to chemotherapy (only or in combination with other treatment modalities), 18 (11.9%) to surgery only, 16 (10.6%) to radiotherapy, one to trastuzumab, and 16 (10.6%) were not exposed to oncologic treatment. Mean cognitive and behavioral outcomes were within normal ranges. Gestational age at birth showed a positive association with Full Scale Intelligence Quotient (FSIQ), with the average FSIQ score increasing by 1.6 points for each week increase in gestational age (95% CI, 0.7 to 2.5; P < .001). No difference in FSIQ was found between treatment types (F[4,140] = 0.45, P = .776). In children prenatally exposed to chemotherapy, no associations were found between FSIQ and chemotherapeutic agent, exposure level, or timing during pregnancy. These results indicate a reassuring follow-up during the critical maturational period of late childhood, when complex functions develop and rely on the integrity of early brain development. However, associations were observed with preterm birth, maternal death, and maternal education.

Amsterdam Reproduction and Development Child Development Amsterdam the Netherlands

Center for Gynecological Oncology Netherlands Cancer Institute Amsterdam the Netherlands

Department of Child and Adolescent Psychiatry and Psychosocial Care Amsterdam UMC University of Amsterdam the Netherlands

Department of Clinical Sciences and Community Health University of Milan Milano Italy

Department of Development and Regeneration Unit Locomotor and Neurological Disorders KU Leuven Belgium

Department of Development and Regeneration Unit of Woman and Child KU Leuven Belgium

Department of Medicine and Surgery Clinic of Obstetrics and Gynecology University of Milan Bicocca San Gerardo Hospital Monza Italy

Department of Obstetric Gynecology University Hospital Kralovske Vinohrady and 3rd Medical Faculty Charles University Prague Czech Republic

Department of Obstetrics and Gynecology Cooper University Health Care Camden NJ

Department of Oncology Laboratory of Experimental Radiotherapy KU Leuven Belgium

Department of Oncology Unit of Gynaecological Oncology KU Leuven Belgium

Department of Oncology Unit of Pediatric Oncology KU Leuven Belgium

Division of Foetomaternal Medicine Department of Obstetrics and Gynaecology UZ Leuven Belgium

Division of Gynaecological Oncology Department of Obstetrics and Gynaecology UZ Leuven Belgium

Division of Pediatric Hemato Oncology Department of Pediatrics UZ Leuven Belgium

Division of Pediatric Neurology Department of Pediatrics UZ Leuven Belgium

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico NICU Milano Italy

Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

UMCU Wilhelmina Children's Hospital Utrecht the Netherlands

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003840
003      
CZ-PrNML
005      
20230425140920.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.22.02005 $2 doi
035    __
$a (PubMed)36634293
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Van Assche, Indra A $u Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium $1 https://orcid.org/0000000312054914
245    10
$a Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study / $c IA. Van Assche, EA. Huis In 't Veld, K. Van Calsteren, M. van Gerwen, J. Blommaert, E. Cardonick, MJ. Halaska, R. Fruscio, M. Fumagalli, J. Lemiere, EM. van Dijk-Lokkart, C. Fontana, H. van Tinteren, J. De Ridder, M. van Grotel, MM. van den Heuvel-Eibrink, L. Lagae, F. Amant
520    9_
$a Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.This multicenter cohort study reports on the long-term effects of prenatal exposure to maternal cancer and its treatment on cognitive and behavioral outcomes in 9-year-old children. In total, 151 children (mean age, 9.3 years; range, 7.8-10.6 years) were assessed using a neurocognitive test battery and parent-report behavioral questionnaires. During pregnancy, 109 children (72.2%) were exposed to chemotherapy (only or in combination with other treatment modalities), 18 (11.9%) to surgery only, 16 (10.6%) to radiotherapy, one to trastuzumab, and 16 (10.6%) were not exposed to oncologic treatment. Mean cognitive and behavioral outcomes were within normal ranges. Gestational age at birth showed a positive association with Full Scale Intelligence Quotient (FSIQ), with the average FSIQ score increasing by 1.6 points for each week increase in gestational age (95% CI, 0.7 to 2.5; P < .001). No difference in FSIQ was found between treatment types (F[4,140] = 0.45, P = .776). In children prenatally exposed to chemotherapy, no associations were found between FSIQ and chemotherapeutic agent, exposure level, or timing during pregnancy. These results indicate a reassuring follow-up during the critical maturational period of late childhood, when complex functions develop and rely on the integrity of early brain development. However, associations were observed with preterm birth, maternal death, and maternal education.
650    _2
$a těhotenství $7 D011247
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    _2
$a kohortové studie $7 D015331
650    _2
$a prospektivní studie $7 D011446
650    12
$a zpožděný efekt prenatální expozice $7 D011297
650    12
$a předčasný porod $7 D047928
650    12
$a nádory $x farmakoterapie $7 D009369
650    _2
$a kognice $7 D003071
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Huis In 't Veld, Evangeline A $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
700    1_
$a Van Calsteren, Kristel $u Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium $u Division of Foetomaternal Medicine, Department of Obstetrics and Gynaecology, UZ Leuven, Belgium $1 https://orcid.org/0000000224386783
700    1_
$a van Gerwen, Mathilde $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands $u Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, the Netherlands
700    1_
$a Blommaert, Jeroen $u Department of Oncology, Unit of Pediatric Oncology, KU Leuven, Belgium $u Department of Oncology, Unit of Gynaecological Oncology, KU Leuven, Belgium $u Department of Oncology, Laboratory of Experimental Radiotherapy, KU Leuven, Belgium $1 https://orcid.org/0000000247469688
700    1_
$a Cardonick, Elyce $u Department of Obstetrics and Gynecology, Cooper University Health Care, Camden, NJ $1 https://orcid.org/0000000322033367
700    1_
$a Halaska, Michael J $u Department of Obstetric Gynecology, University Hospital Kralovske Vinohrady and 3rd Medical Faculty, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000160552569 $7 xx0062494
700    1_
$a Fruscio, Robert $u Department of Medicine and Surgery, Clinic of Obstetrics and Gynecology, University of Milan-Bicocca, San Gerardo Hospital, Monza, Italy $1 https://orcid.org/0000000156882194
700    1_
$a Fumagalli, Monica $u Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy $u Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, NICU, Milano, Italy
700    1_
$a Lemiere, Jurgen $u Department of Oncology, Unit of Pediatric Oncology, KU Leuven, Belgium $u Division of Pediatric Hemato-Oncology, Department of Pediatrics, UZ Leuven, Belgium $1 https://orcid.org/0000000215750889
700    1_
$a van Dijk-Lokkart, Elisabeth M $u Department of Child and Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, the Netherlands $u Amsterdam Reproduction and Development, Child Development, Amsterdam, the Netherlands
700    1_
$a Fontana, Camilla $u Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, NICU, Milano, Italy $1 https://orcid.org/0000000282177824
700    1_
$a van Tinteren, Harm $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
700    1_
$a De Ridder, Jessie $u Division of Pediatric Neurology, Department of Pediatrics, UZ Leuven, Belgium $u Department of Development and Regeneration, Unit Locomotor and Neurological Disorders, KU Leuven, Belgium $1 https://orcid.org/0000000285557822
700    1_
$a van Grotel, Martine $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
700    1_
$a van den Heuvel-Eibrink, Marry M $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u UMCU-Wilhelmina Children's Hospital, Utrecht, the Netherlands
700    1_
$a Lagae, Lieven $u Department of Development and Regeneration, Unit of Woman and Child, KU Leuven, Belgium $u Division of Pediatric Neurology, Department of Pediatrics, UZ Leuven, Belgium
700    1_
$a Amant, Frédéric $u Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands $u Department of Oncology, Unit of Gynaecological Oncology, KU Leuven, Belgium $u Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, UZ Leuven, Belgium $1 https://orcid.org/0000000254524905
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 41, č. 8 (2023), s. 1527-1532
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36634293 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140916 $b ABA008
999    __
$a ok $b bmc $g 1924485 $s 1190049
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 8 $d 1527-1532 $e 20230112 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options